NCT05847920 is a Phase 2 clinical trial of SHR-2010 Injection in Primary IgA Nephropathy, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd.

Who is sponsoring NCT05847920?

NCT05847920 is sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd.

What drugs are being tested in NCT05847920?

Interventions in NCT05847920: SHR-2010 Injection, Placebo.

What condition does NCT05847920 study?

NCT05847920 studies Primary IgA Nephropathy.

Is NCT05847920 still recruiting?

NCT05847920 is currently terminated. Last updated 5 March 2025.

Last reviewed 2025-03-05 · How we verify

NCT05847920

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

Terminated Phase 2 Last updated 5 March 2025

What this trial tests

Phase 2 trial testing SHR-2010 Injection in Primary IgA Nephropathy in 53 participants. Terminated before completion.

Timeline

4 June 2023

Primary endpoint
20 January 2025

20 January 2025

Quick facts

Lead sponsor	Guangdong Hengrui Pharmaceutical Co., Ltd
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	53
Start date	4 June 2023
Primary completion	20 January 2025
Estimated completion	20 January 2025
Sites	1 location across China

Drugs / interventions tested

SHR-2010 Injection — full drug profile →
Placebo

Conditions studied

Primary IgA Nephropathy — all drugs for Primary IgA Nephropathy →

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd — full company profile →

Who can join

Adults 18 to 70, any sex, with Primary IgA Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is being conducted to evaluate the efficacy, and safety of SHR - 2010 injection in patients with primary IgA nephropathy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Non-immunosuppressive treatment for IgA nephropathy.
Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, et al · · 2024 · cited 20× · PMID 38299639 · DOI 10.1002/14651858.cd003962.pub3
Research progress on the lectin pathway of complement in IgA nephropathy
Yu X, Gao H, Sun X. ·
Advances in Complement-Targeted Therapy for IgA Nephropathy.
Lu M, Li G. · · 2026 · PMID 41608159 · DOI 10.1159/000550108

Verify or expand the search:

Other recruiting trials for Primary IgA Nephropathy

Currently open trials in the same condition.

NCT06137768 — A Trial of HRS-5965 Tablets in Primary IgA Nephropathy · Phase 2 · active not recruiting
NCT05797610 — A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA · Phase 3 · recruiting
NCT04557462 — A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in P · Phase 3 · recruiting

Other Guangdong Hengrui Pharmaceutical Co., Ltd trials

Trials by the same sponsor.

NCT06939504 — A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects · Phase 1 · completed
NCT06786455 — Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent · Phase 2 · completed
NCT06955598 — A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcut · Phase 1 · completed
NCT06554509 — Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis · Phase 2, PHASE3 · recruiting
NCT06514963 — A Trial of HRS-9813 in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05847920 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Hengrui Pharmaceutical Co., Ltd
Last refreshed: 5 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05847920.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing